Immunophotonics has announced the FDA’s decision to allow the U.S. clinical trial of IP-001 to proceed with the enrollment of patients based on the company’s investigational new drug (IND) application. This extends the company’s INJECTABL-1 trial to the treatment of metastatic colorectal cancer, lung cancer, and sarcoma patients in the USA. Read more (Official Press Release)
![](https://immunophotonics.com/wp-content/uploads/2023/05/IND-press-release-05.2023-v.2.png)